EP2025684A1 — Glucagon analogues
Assigned to Zealand Pharma AS · Expires 2009-02-18 · 17y expired
What this patent protects
The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject, comprising administering to the subject a glucagon analogue peptide which has improved selectivity for the GLP-1 receptor as compared to human glucagon. The invention al…
USPTO Abstract
The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject, comprising administering to the subject a glucagon analogue peptide which has improved selectivity for the GLP-1 receptor as compared to human glucagon. The invention also provides novel glucagon analogue peptides having increased selectivity for the GLP-1 receptor as compared to human glucagon, and their use for the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.